Vifor Boosts US Nephrology Prospects With Janssen Pact
Vifor: Selling Invokana In DKD Could Aid Veltassa’s US sales
Executive Summary
Vifor has boosted its US nephrology prospects with a pact with Janssen to jointly market Invokana in diabetic kidney disease.
You may also be interested in...
Bayer Focusing On Early CKD Testing In Kerendia US Launch
The company, which set a list price of $19 per day, sees awareness of diagnosing chronic kidney disease in type 2 diabetes patients as the top challenge for newly approved finerenone in the US.
Deal Watch: Allergan Keeps After Hair Loss With Exicure Deal
Allergan has tried to go after alopecia in the past; Exicure brings a new spherical nucleic acid (SNA) technology. In other recent deals, AstraZeneca sells Seroquel, Losec rights to Germany’s Cheplapharm.
Deal Watch: Gilead Hopes Glympse’s Synthetic Biomarkers Can Optimize NASH Trials
Gilead partners with Glympse to optimize NASH trials, while Ironwood will work with Pear on digital therapies for GI disorders. An alliance between Leo and Ubiquigent yields an option agreement around two novel compounds.